Quetiapine, olanzapine and haloperidol affect human plasma lipid peroxidation in vitro

Neuropsychobiology

Volumn 63, Issue 4, 2011, Pages 197-201

  Dietrich Muszalska, Anna ^a   Kontek, Bogdan ^b   Rabe Jabłońska, Jolanta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

Author keywords

Antipsychotics; Haloperidol; Lipid peroxidation; Olanzapine; Oxidative stress; Quetiapine

Indexed keywords

ACID CITRATE DEXTROSE; DIMETHYL SULFOXIDE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; LIPID BLOOD LEVEL; LIPID PEROXIDATION; MALE; NORMAL HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; HALOPERIDOL; HUMANS; LIPID PEROXIDATION; MALE; PLASMA; SPECTROPHOTOMETRY; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 79952733384     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321623     Document Type: Article

References (38)

1. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R: Tardive dyskinesia in the era of typical and atypical antipsychotics. 1. Pathophysiology and mechanisms of induction. Can J Psychiatry 2005; 50: 541-547. (Pubitemid 43161786)
2. Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV: Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990; 15: 535-539. (Pubitemid 20298448)
3. Kulkarni SK, Naidu PS: Tardive dyskinesia: an up date. Drugs Today 2001; 137: 97-119.
4. Balijepalli S, Kenchappa RS, Boyd MR, Ravindranath V: Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics. Neurochem Int 2001; 38: 425-435. (Pubitemid 32166900)
5. Cadet JL, Lohr JB, Jeste DV: Free radicals and tardive dyskinesia. Trends Neurosci 1986; 9: 107-108.
6. Sachdev PS: The current status of tardive dyskinesia. Aust NZ J Psychiatry 2000; 34: 355-369. (Pubitemid 30389406)
7. Cadet JL, Lohr JB, Jeste DV: Tardive dyskinesia and schizophrenic burnout: the possible involvement of cytotoxic free radicals; in Henn FA, DeLisi LE (eds): Handbook of Schizophrenia: The Neurochemistry and Pharmacology of Schizophrenia. Amsterdam, Elsevier, 1987, pp 425-438.
8. Möller HJ: Novel antipsychotics in the longterm treatment of schizophrenia. World J Biol Psychiatry 2004; 5: 9-19.
9. Hong WW, Rak IW, Ciuryla VT, Wilson AM, Kylstra JW, Meltzer HY, Carpenter WTJR, Lehman A, Arvanitis LA: Medicalclaims databases in the design of a healthoutcomes comparison of quetiapine ('Seroquel') and usual-care antipsychotic medication. Schizophr Res 1998; 22: 51-58. (Pubitemid 28338124)
10. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ, WFSBP Task Force on Treatment Guidelines for Schizophrenia: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. 1. Acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6: 132-191.
11. Sacchetti E, Valsecchi P: Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report. Int Clin Psychopharmacol 2003; 18: 357-359. (Pubitemid 38183490)
12. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin Psychiatry 1998; 59: 22-33. (Pubitemid 29001829)
13. Rice-Evans CA: Formation of free radicals and mechanisms of action in normal biochemical processes and pathological states; in Rice-Evans CA, Burdone RH (eds): Free Radical Damage and Its Control. Amsterdam, Elsevier, 1994, pp 131-153.
14. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI: N-acetyl cysteine as a glutathione precursor for schizophrenia - A double-blind, randomized, placebo- controlled trial. Biol Psychiatry 2008; 64: 361-368.
15. Horrobin DF: The membrane phospholipids hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998; 30: 193-208. (Pubitemid 28189552)
16. Fenton WS, Hibbeln J, Knable M: Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia. Biol Psychiatry 2000; 47: 8-21. (Pubitemid 30016075)
17. Ross BM: Phospholipid and eicosanoid signaling disturbances in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 407-412. (Pubitemid 37464050)
18. Mahadik SP, Scheffer RE: Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 45-54. (Pubitemid 26321117)
19. Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, Gaha L: Oxidative stress involvement in schizophrenia pathophysiology. Encephale 2006; 32: 244-252. (Pubitemid 43670234)
20. Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, Bennett C, Ranjekar PK, Mahadik SP: Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry 2003; 53: 56-64. (Pubitemid 36050936)
21. Dietrich-Muszalska A, Olas B, Rabe-Jablonska J: Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005; 16: 386-391. (Pubitemid 41564335)
22. Du Bois TM, Deng C, Huang XF: Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 878-888. (Pubitemid 41080107)
23. Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, Shen Y, Zhou DF: Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006; 81: 291-300. (Pubitemid 43107705)
24. Dietrich-Muszalska A, Olas B: Isoprostanes as indicators of oxidative stress in schizophrenia. World J Biol Psychiatry 2007; 4: 1-6.
25. Mahadik SP, Mukherjee S, Correnti EE, Scheffer R: Elevated levels of lipid peroxidation products in plasma of drug-naive patients at the onset of psychosis. Schizophr Res 1995; 15: 66.
26. Peet M, Laugharne J, Rangarajan N, Reynolds GP: Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychophamacol 1993; 8: 151-153. (Pubitemid 23294920)
27. Gama CS, Salvador M, Andreazza AC, Kapczinski F, Silva Belmonte-de-Abreu P: Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 512-515.
28. Dietrich-Muszalska A: The impact of haloperidol on lipids peroxidation in human blood platelets and plasma at in vitro studies. Psychiatr Psychol Klin 2004; 3: 150-156.
29. Gama CS, Salvador M, Andreazza AC, Lobato MI, Berk M, Kapiczinski F, Belmontede- Abreu PS: Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neurosci Lett 2008; 433: 270-273.
30. Pai BN, Janakiramaiah N, Gangadhar BN, Ravindranath V: Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration. Biol Psychiatry 1994; 36: 489-491.
31. Sagara Y: Induction of reactive oxygen species in neurones by haloperidol. J Neurochem 1998; 71: 1002-1012. (Pubitemid 28390254)
32. Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Haile CN, Kosten TA, Kosten TR: Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J Clin Psychiatry 2007; 68: 754-760. (Pubitemid 46841859)
33. Miyamoto S, Duncan GE, Marx CE, Lieberman JA: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10: 79-104. (Pubitemid 40139590)
34. Kropp S, Kern V, Lange K, Degner D, Hajak G, Kornhuber J, Ruther E, Emrich HM, Schneider U, Bleich S: Oxidative stress during treatment with first- and second-generation antipsychotics. J Neuropsychiatry Clin Neurosci 2005; 17: 227-231. (Pubitemid 41350611)
35. Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, Turankar A: Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004; 49: 205-209. (Pubitemid 38594573)
36. Parikh V, Khan MM, Mahadik SP: Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2003; 37: 43-51. (Pubitemid 35449770)
37. Xu H, Wang H, Zhuang L, Yan B, Yingxin Y, Wei Z, Zhang Y, Dyck LE, Richardson SJ, He J, Li X, Kong J, Li XM: Demonstration of an anti-oxidative stress mechanism of quetiapine. FEBS J 2008; 275: 3718-3728.
38. Vesely C, Kufferle B, Brucke T, Kacper S: Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine. Int Clin Psychopharmacol 2000; 15: 57-60.(Pubitemid 30058142)